Common Reasons for Supplementary Information Requests in Overseas Registration of Implantable Medical Devices

Common reasons for supplementary information requests in overseas registration of implantable medical devices mainly fall into five categories: inconsistency between the product risk classification and the regulatory requirements of the target country; technical files referencing standards or test methods not accepted by the target regulator; insufficient clinical evaluation or clinical evidence; inadequate alignment of quality management system documentation with ISO 13485/MDSAP or other applicable norms; and incomplete localization of labels, instructions, and local agent authorization documents. Companies should confirm at the project initiation stage whether the product falls within the medical device regulatory scope of the target country, determine the risk class based on intended use, implantation site, and material characteristics, and establish the registration pathway and applicant entity. Performance verification, biocompatibility, sterilization validation, and animal study data accumulated during NMPA, CE, or FDA submissions can be reused, but must be compared item by item against the target country's technical review guidelines, with particular attention to differences in test conditions, sample sizes, and acceptance criteria. Other common risks include missing post-market surveillance plans, incomplete change management plans, and failure to appoint a stable local authorized representative, all of which can lead to communication breakdowns. Companies are advised to build a core technical documentation library, prepare gap analysis tables based on GHWP member country requirements, proactively obtain certificates of free sale and proof of marketing authorization in the country of origin, and work with regulatory agents familiar with local regulations to complete document conversion, thereby reducing the number of deficiency rounds and shortening the review timeline.

Key Summary

Implantable medical devices are more likely than ordinary devices to trigger supplementary information requests during overseas registration. The fundamental reason is that they directly contact human tissue or blood, requiring higher-level long-term risk evaluation, and regulators in each country demand more detailed evidence of safety and effectiveness. A deficiency request is not merely a formatting issue; it indicates that the technical documentation submitted is insufficient to demonstrate the product's safety and effectiveness in the target market.

Companies must recognize that the reasons for supplementary information requests vary by country or region. Some arise from differences in risk classification, some from mismatched clinical evaluation pathways, and others from inadequate alignment between quality management system documentation and local regulations. Therefore, a review comment from one country should not be directly applied to another; instead, companies should systematically assess the requirements of each target market.

Applicable Scenarios and Core Issues

Handling overseas registration for implantable devices requires answering four fundamental questions: Is the product within the medical device regulatory scope of the target country? What risk class should be assigned based on intended use and invasiveness? Which registration pathway and applicant entity are appropriate? Which existing documents from NMPA, CE, FDA, or ISO 13485 can be reused?

Regulatory Scope

Some implants may be classified as drugs, combination products, or fall outside the definition of a medical device. Companies should consult the target country's official classification list or request a pre-classification to avoid preparing documentation in the wrong framework.

Risk Class and Registration Pathway

Implantable devices are typically Class IIb or Class III. Most countries require premarket review or registration assessment, and some require post-market clinical follow-up studies. Companies should confirm as early as possible whether a clinical trial exemption is possible and whether clinical data from the country of origin can be extrapolated.

Reusability of Existing Documentation

Test reports from NMPA, CE, or FDA can reduce repetitive verification costs, but it is essential to verify whether the referenced standards are accepted by the target country. For example, the version of ISO 10993 used for biocompatibility testing, standards for sterilization validation, and GLP qualifications for animal studies may vary.

Localization Documents

Labels, instructions for use, patient cards, and physician manuals must be translated into the local language. Units of measurement and warning statements must also comply with local regulations. In addition, a local agent or authorized representative in the target country must be appointed, and a stable authorization document must be submitted.

Documentation and Evidence

Core technical documents for overseas registration of implantable devices typically include the product technical documentation, risk management report, biocompatibility test report, clinical evaluation or clinical trial data, sterilization validation report, packaging and shelf-life validation report, label and instruction drafts, quality management system certificate, and certificate of free sale from the country of origin.

Among these, the risk management report and clinical evidence are the most common triggers for deficiency requests. Risk management for implantable devices must go beyond performance, materials, and manufacturing processes to include analysis of short- and long-term risks in the target population, such as allergic reactions, implant migration, degradation product toxicity, and MRI compatibility. The clinical evaluation should cover equivalence arguments with similar products or clinical trial data, and explain the target population and indicated uses.

Common issues include:

• Product technical requirements or performance indicators do not align with target country standards, such as referencing an outdated ISO standard.
• Biocompatibility testing is incomplete, and chronic toxicity or genotoxicity tests have not been performed based on contact duration and contact type.
• Animal study protocols or data for implantable devices do not meet the target country's GLP or specific guidance requirements.
• Clinical evaluation reports do not cover the target population or have insufficient long-term follow-up data.
• The sterilization method is not appropriately chosen, and sterilization effectiveness has not been verified under both maximum and minimum load conditions.
• Packaging and shelf-life validation does not consider the relationship between accelerated aging and real-time aging.

For multi-country registrations, it is advisable to structure the technical documents as a modular library and generate country-specific gap lists, avoiding the need to recompile documents for every application.

Common Mistakes

Based on review experience, deficiency requests for implantable devices often stem from early-stage judgment errors. Common mistakes include unclear division of responsibilities, inadequate document conversion, or ignoring local regulatory updates.

• Incorrect risk classification, assigning an implantable device to a lower risk class and submitting incomplete documentation.
• Direct use of CE registration files without checking the target country's additional requirements for type testing items, test standards, and clinical evidence.
• Poor translation quality, leading to ambiguity in technical terms, warnings, or clinical descriptions.
• Lack of response to special target country requirements, such as a separate stability test for certain implantable devices.
• Choosing an unstable local agent, or having agent authorization documents that do not match the manufacturer's information, affecting review communication.
• No post-market surveillance plan, or a plan that does not cover the long-term collection of clinical data required for implantable devices.

Company Preparation Checklist

To reduce the number of deficiency rounds, companies should complete the following pre-submission checklist:

• Establish a cross-functional team including R&D, quality, clinical, and regulatory personnel, and designate a single regulatory lead.
• Complete the product classification determination for the target country, and request an official pre-classification opinion where necessary.
• Create an inventory of existing test and validation reports, marking which items are reusable and which need supplementation.
• Commission accredited testing institutions to perform required additional tests following target country recognized standards.
• Prepare the risk management report and clinical evaluation report in accordance with the target country's required format.
• Complete localized translation of labels and instructions, and have a local reviewer confirm accuracy.
• Sign a local agent agreement, obtain a formal power of attorney, and provide local contact details.

AIMEILI Perspective

The most common misjudgment companies make is assuming that after obtaining CE or FDA registration, registrations in other countries merely involve translation and simple submission. For implantable products registering in GHWP member countries, it is often necessary to re-evaluate based on local usage environments, ethnic differences, and clinical accessibility. For example, anatomical fit data for certain implants in Asian populations may differ from European or American populations, and regulators may request additional suitability data.

In the early stages of a project, companies should conduct a regulatory gap analysis rather than immediately starting new testing. We recommend that companies first review the target country's technical review guidelines, compare them item by item with existing documentation, and form a gap table before deciding on the order of investments. This approach saves time and avoids submitting the same incomplete dossiers to multiple countries simultaneously.

Reusable data typically includes physicochemical properties, material characterization, and biocompatibility—the generally accepted verification data—provided that the testing institution's qualifications, test standards, and report format are accepted by the target country. Localization is required for clinical evaluation, labels and instructions, risk management requirements related to local regulations, post-market surveillance plans, and complaint handling procedures.

A local agent is not merely a file recipient but a critical communication channel during review. Companies should choose an agent familiar with implantable devices and willing to share responsibility for changes and adverse event reporting with the manufacturer. At the same time, ensure that control of the certificate remains in the manufacturer's hands to avoid registration cancellations due to agent changes.

For multi-country registration, we recommend managing document versions using eCTD or similar electronic formats and tracking deficiency requirements from each country. Creating a 'deficiency confirmation table' for the same set of technical files across countries allows the team to quickly identify modification points after each review comment, significantly reducing repetitive work and deficiency risk.

Common Follow-up Questions

How long does the deficiency response period usually take? Will it affect the launch timeline?

The response period varies by country, typically ranging from 30 to 90 working days. If a company is unprepared, deficiency responses may add time for queueing, testing, or clinical trials, potentially extending the total timeline by more than six months. Therefore, we recommend that companies carefully review local review guidelines before submission and aim to submit a complete dossier in the first round.

If clinical data is insufficient, can the equivalent product (same type) pathway be used?

Some countries allow equivalence arguments referencing clinical literature or data from the same type of product, but a sufficient equivalence comparison is required, including material, structure, implantation site, and indications. If differences are significant, regulators may still require supplementary clinical trials.

If we already have NMPA registration, can it be directly used for overseas applications?

NMPA registration documents are an important foundation but cannot be used directly. Overseas registration requires that language, standards, and evidence formats be accepted by the target country. Companies should treat NMPA documents as the original evidence source and reorganize and convert them according to the target country's requirements, especially for clinical evaluation and risk management, which must be rewritten based on local regulations.

Related Reading

• How to prepare performance verification documentation for overseas registration of monitoring equipment?
• How to localize labels and instructions for overseas registration of imaging equipment?
• What are common reasons for supplementary information requests in overseas registration of imaging equipment?
• Why does the registration cycle extend for imaging equipment overseas registration?
• What are the risk management documentation requirements for overseas registration of home medical devices?
• How to prepare clinical evaluation data for overseas registration of software medical devices?

Publication Information

Published: 2026-08-19 20:39   Updated: 2026-08-19 20:39

Content Author: AIMEILI Regulatory Editorial Department   Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Preference given to official regulatory bodies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary reference.

Application Boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements, testing conclusions, or legal opinions from the target country's regulatory authorities.